目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast (2021-2026)
2.3.1.4 CAGR projections
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET
2.9 GROWTH RATE ASSUMPTIONS
2.10 COVID-19 HEALTH ASSESSMENT
2.11 COVID-19 ECONOMIC ASSESSMENT
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET

3 EXECUTIVE SUMMARY (Page No. - 51)
FIGURE 11 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2021 VS. 2026 (USD MILLION)
FIGURE 13 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 LIQUID BIOPSY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 56)
4.1 LIQUID BIOPSY MARKET OVERVIEW
FIGURE 18 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE LIQUID BIOPSY MARKET
4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 19 THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026
FIGURE 20 THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 22 CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026
FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 24 REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.8 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE LIQUID BIOPSY MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 61)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 26 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of cancer
TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
5.2.1.3 Increasing preference for noninvasive treatment procedures
5.2.2 RESTRAINTS
5.2.2.1 The lower sensitivity of certain liquid biopsies
5.2.3 OPPORTUNITIES
5.2.3.1 The growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario
5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS
5.4.1 LIQUID BIOPSY MARKET
FIGURE 27 REALISTIC SCENARIO
FIGURE 28 PESSIMISTIC SCENARIO
FIGURE 29 OPTIMISTIC SCENARIO
5.5 PRICING ANALYSIS
TABLE 2 PRICE OF LIQUID BIOPSY PRODUCTS (2021)
5.6 PATENT ANALYSIS
5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS
5.7 VALUE CHAIN ANALYSIS
FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
FIGURE 31 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET
FIGURE 32 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 DEGREE OF COMPETITION
5.10 REGULATORY LANDSCAPE
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.4.2 Mexico
5.10.5 MIDDLE EAST
5.10.6 AFRICA
5.11 TECHNOLOGY ANALYSIS
5.12 PESTLE ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.13.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million)
5.13.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons)
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE (Page No. - 81)
6.1 INTRODUCTION
TABLE 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
6.2 ASSAY KITS
6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 5 KEY PRODUCTS IN THE ASSAY KITS MARKET
TABLE 6 LIQUID BIOPSY MARKET FOR ASSAY KITS, BY REGION, 2019-2026 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT
TABLE 7 KEY PRODUCTS IN THE INSTRUMENTS MARKET
TABLE 8 LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY REGION, 2019-2026 (USD MILLION)
6.4 SERVICES
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH
TABLE 9 LIQUID BIOPSY MARKET FOR SERVICES, BY REGION, 2019-2026 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS (Page No. - 87)
7.1 INTRODUCTION
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
TABLE 10 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
7.2 CIRCULATING TUMOR CELLS (CTC)
7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 11 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019-2026 (USD MILLION)
7.3 CIRCULATING TUMOR DNA (CTDNA)
7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER
TABLE 12 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2019-2026 (USD MILLION)
7.4 CELL-FREE DNA (CFDNA)
7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 13 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2019-2026 (USD MILLION)
7.5 EXTRACELLULAR VESICLES (EVS)
7.5.1 EVS ARE STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT
TABLE 14 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2019-2026 (USD MILLION)
7.6 OTHER CIRCULATING BIOMARKERS
TABLE 15 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019-2026 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY (Page No. - 94)
8.1 INTRODUCTION
8.1.1 PRIMARY NOTES
8.1.1.1 Key industry insights
TABLE 16 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 17 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019-2026 (USD MILLION)
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 18 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019-2026 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION (Page No. - 97)
9.1 INTRODUCTION
TABLE 19 LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
9.2 CANCER APPLICATIONS
TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION)
TABLE 21 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
TABLE 22 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
9.2.1 LUNG CANCER
9.2.1.1 Increasing prevalence of lung cancer to propel the market growth
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 24 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2019-2026 (USD MILLION)
9.2.2 BREAST CANCER
9.2.2.1 Increasing government funding for breast cancer research is expected to drive the market growth
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2019-2026 (USD MILLION)
9.2.3 COLORECTAL CANCER
9.2.3.1 Increasing prevalence of colorectal cancer to propel the market growth
TABLE 27 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 28 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2019-2026 (USD MILLION)
9.2.4 PROSTATE CANCER
9.2.4.1 Growing number of prostate cancer patients to drive the growth of this market
TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 30 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2019-2026 (USD MILLION)
9.2.5 MELANOMA
9.2.5.1 Increasing need for the early diagnosis of genetically mutated tumors to drive market growth
TABLE 31 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 32 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2019-2026 (USD MILLION)
9.2.6 OTHER CANCERS
TABLE 33 GLOBAL CANCER INCIDENCE, 2020
TABLE 34 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2019-2026 (USD MILLION)
9.3 NON-CANCER APPLICATIONS
9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT
TABLE 35 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (Page No. - 110)
10.1 INTRODUCTION
TABLE 36 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
10.2 THERAPY SELECTION
10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 37 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2019-2026 (USD MILLION)
10.3 TREATMENT MONITORING
10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS
TABLE 38 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2019-2026 (USD MILLION)
10.4 RECURRENCE MONITORING
10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 39 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2019-2026 (USD MILLION)
10.5 EARLY CANCER SCREENING
10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH
TABLE 40 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019-2026 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY END USER (Page No. - 116)
11.1 INTRODUCTION
TABLE 41 LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
11.2 REFERENCE LABORATORIES
11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT
TABLE 42 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
11.3 HOSPITALS AND PHYSICIAN LABORATORIES
11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT
TABLE 43 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
11.4 ACADEMIC & RESEARCH CENTERS
11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
TABLE 44 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019-2026 (USD MILLION)
11.5 OTHER END USERS
TABLE 45 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY REGION (Page No. - 121)
12.1 INTRODUCTION
TABLE 46 LIQUID BIOPSY MARKET, BY REGION, 2019-2026 (USD MILLION)
12.2 NORTH AMERICA
TABLE 47 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 50 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 51 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 53 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.2.1 US
12.2.1.1 The increasing prevalence of cancer is a key factor expected to drive market growth in the US
TABLE 55 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 56 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 57 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 58 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 59 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 60 US: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.2.2 CANADA
12.2.2.1 The availability of various cancer screening programs in Canada is expected to drive market growth in Canada
TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 62 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 63 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 64 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 65 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 66 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.3 EUROPE
TABLE 67 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 68 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 69 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 70 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 71 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 72 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 73 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
TABLE 74 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 75 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 76 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 77 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 78 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 79 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.3.2 UK
12.3.2.1 Increasing number of diagnostic laboratories in the UK to propel the market growth
TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 81 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 82 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 83 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 85 UK: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Rising R&D expenditure in France to drive the market growth
TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 87 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 88 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 89 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 90 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 91 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.3.4 REST OF EUROPE
TABLE 92 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 93 ROE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 94 ROE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 95 ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 96 ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 97 ROE: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 34 APAC: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 98 APAC: LIQUID BIOPSY MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 99 APAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 100 APAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 101 APAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 102 APAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 103 APAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 104 APAC: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.4.1 CHINA
12.4.1.1 Growing public access to advanced healthcare facilities to drive the market growth in China
TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 106 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 107 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 108 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 109 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.4.2 JAPAN
12.4.2.1 Universal healthcare reimbursement policy to drive the market growth in Japan
TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 112 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 113 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 114 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 115 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 116 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Increasing private & public investments in the country’s healthcare system is expected to drive the market growth
TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 118 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 119 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 120 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 121 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 122 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.4.4 REST OF ASIA PACIFIC
TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 124 ROAPAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 125 ROAPAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 126 ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 127 ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 128 ROAPAC: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)
12.5 REST OF THE WORLD
TABLE 129 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 130 ROW: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019-2026 (USD MILLION)
TABLE 131 ROW: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 132 ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
TABLE 133 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019-2026 (USD MILLION)
TABLE 134 ROW: LIQUID BIOPSY MARKET, BY END USER, 2019-2026 (USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 161)
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE LIQUID BIOPSY MARKET
TABLE 135 OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 35 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE LIQUID BIOPSY MARKET
13.4 MARKET SHARE ANALYSIS
FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020)
TABLE 136 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
13.5 COMPANY EVALUATION QUADRANT
13.5.1 LIST OF EVALUATED VENDORS
13.5.2 STARS
13.5.3 EMERGING LEADERS
13.5.4 PERVASIVE PLAYERS
13.5.5 PARTICIPANTS
FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES
FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
13.7 COMPETITIVE BENCHMARKING
FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET
TABLE 137 COMPANY PRODUCT TYPE FOOTPRINT
TABLE 138 COMPANY GEOGRAPHICAL FOOTPRINT
13.8 COMPETITIVE SCENARIO
13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS
TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
13.8.2 DEALS
TABLE 140 KEY DEALS
13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS
TABLE 141 OTHER KEY DEVELOPMENTS

14 COMPANY PROFILES (Page No. - 173)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 QIAGEN N.V.
TABLE 142 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
14.1.2 F. HOFFMANN-LA ROCHE
TABLE 143 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
14.1.3 MYRIAD GENETICS, INC.
TABLE 144 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
14.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 145 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
14.1.5 GUARDANT HEALTH, INC.
TABLE 146 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020)
14.1.6 BIO-RAD LABORATORIES
TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 45 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
14.1.7 ILLUMINA, INC.
TABLE 148 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 46 ILLUMINA: COMPANY SNAPSHOT (2020)
14.1.8 EXACT SCIENCES
TABLE 149 EXACT SCIENCES: BUSINESS OVERVIEW
FIGURE 47 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
TABLE 150 SYSMEX INOSTICS: BUSINESS OVERVIEW
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
14.1.10 BIOCEPT, INC.
TABLE 151 BIOCEPT, INC.: BUSINESS OVERVIEW
FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2020)
14.1.11 MDX HEALTH
TABLE 152 MDX HEALTH: BUSINESS OVERVIEW
FIGURE 50 MDX HEALTH: COMPANY SNAPSHOT (2020)
14.2 OTHER PLAYERS
14.2.1 NEOGENOMICS, INC.
14.2.2 ANGLE PLC
14.2.3 EPIGENOMICS AG
14.2.4 MENARINI-SILICON BIOSYSTEMS
14.2.5 VORTEX BIOSCIENCES, INC.
14.2.6 EXOSOME DIAGNOSTICS, INC.
14.2.7 MEDGENOME INC.
14.2.8 AGENA BIOSCIENCE, INC.
14.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
14.2.10 FREENOME HOLDINGS, INC.
14.2.11 STRAND LIFE SCIENCES
14.2.12 LUNGLIFE AI, INC.
14.2.13 LUCENE HEALTH INC.
14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 224)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS